MRK · available-data snapshot
Merck & Co., Inc. (MRK): Available-Data Snapshot
TickerWorth does not publish a DCF fair value for Merck & Co., Inc. (MRK); the reason is set out below. What its filings and market data do show is below. The snapshot also sets out its trading multiples against 5 peers. Snapshot as of Oct 19, 2026.
Model by Miraaj Patel · generated from public market data · Updated Oct 19, 2026 · How these pages are made
Why is there no fair value for MRK?
We do not publish a fair value for Merck & Co., Inc.. What we can say from its filings and market data is below.
What is MRK's TickerWorth Score?
Middle of the pack — real strengths and real weaknesses
Compared with Healthcare companies in US
Its strongest point: recent price trend has been strong. Its weakest: balance sheet looks stretched.
- Value · 41 of 100
Cheaper than 41% of Healthcare companies in US
- Price vs worth · 42 of 100
- Quality · 50 of 100
More profitable than 50% of Healthcare companies in US
- Financial health · 28 of 100
Financially stronger than 28% of Healthcare companies in US
- Growth · 66 of 100
Growing faster than 66% of Healthcare companies in US
- Momentum · 89 of 100
Outperformed 89% of Healthcare companies in US over the past year
Confidence: High confidence · Scored
Get the Undervalued Company of the Week.
- Price
- $145.95
- Market cap
- $360,
083, 685, 376 - 52-week high
- $156.92
- 52-week low
- $82.01
- Currency
- USD
- Exchange
- NYSE
Snapshot of Oct 19, 2026, quote time not published · Prices are delayed.
What we can say
We don't publish a discounted-cash-flow fair value for Merck & Co., Inc. (MRK) because the free data sources we rely on don't expose the multi-year financials a DCF needs — common for small or thinly-covered listings. Rather than invent numbers, this page shows an honest snapshot of what the public data does support: the current price and size, any relative valuation multiples that exist, a book-value view, and a price-based read. Treat it as a descriptive starting point, not a valuation and not investment advice.
Read the full reasoning
On the numbers we do have, MRK trades at a recent price of $145.95, a market capitalisation of about $360,083,685,376, sitting 85% of the way up its 52-week range ($82.01–$156.92), on the NYSE.
The standard alternative to a DCF is relative valuation — comparing MRK's trading multiples against its direct industry peers. Here that gives P/E of 115.8× (richer than the peer median of 38.9×); Fwd P/E of 15.7× (cheaper than the peer median of 17.6×); P/B of 8.6× (richer than the peer median of 6.4×); P/S of 5.4× (cheaper than the peer median of 6.2×); EV/EBITDA of 14.1× (cheaper than the peer median of 18.5×); Dividend yield of 2.3% (in line with the peer median of 2.4%). A cheaper multiple than peers can flag a discount or a market that expects weaker growth; it is a comparison, not a recommendation.
The asset, or book-value, lens is the classic tool for asset-heavy businesses and financials. MRK shows a price-to-book (P/B) of 8.59 and book value of $16.99 per share. Price-to-book compares the market price to the accounting net-asset value per share; below 1.0 can mean a discount to net assets or that the market is pricing in trouble — descriptive either way, never a buy signal on its own.
Finally, a price-based read — explicitly not a valuation. MRK is in an up-trend (price above both its 50- and 200-day averages), trading -7.0% from its 52-week high. Over the past year the stock is +69.1%. Moving-average trend and 52-week position describe where the stock has traded; they say nothing about what it is worth.
MRK vs peers
Direct industry peers.
| Multiple | MRK | Peer median | Read |
|---|---|---|---|
| P/E | 115.8× | 38.9× | richer than |
| Fwd P/E | 15.7× | 17.6× | cheaper than |
| P/B | 8.6× | 6.4× | richer than |
| P/S | 5.4× | 6.2× | cheaper than |
| EV/EBITDA | 14.1× | 18.5× | cheaper than |
| Dividend yield | 2.3% | 2.4% | in line with |
What does Merck & Co., Inc. do?
What does it do?
Merck & Co., Inc. operates as a healthcare company worldwide. It operates in the Drug Manufacturers - General industry (Healthcare sector), headquartered in United States. The company employs roughly 73,000 people.
How does it make money?
The business turns $66.6B in annual revenue into profit. Out of every $100 of sales, about $0 is left as operating profit (operating margin of -0.2%), after a 76% gross margin on the products/services it sells. After all costs, taxes and interest, 4.8% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks stretched: carries moderate debt (1.3× equity), can just cover its short-term bills (1.3× current ratio), and is currently profitable.
Who at MRK filed insider trades?
| Date | Insider | Relationship | What happened | Value | Filing |
|---|---|---|---|---|---|
| Guindo Chirfi | EVP, Access, Policy & Comms | Open-market sale | $1,350,000.00 | Form 4 for Guindo Chirfi (opens sec.gov in a new tab) | |
| Zachary Jennifer | EVP, General Counsel | Option exercise | $4,891,727.66 | Form 4 for Zachary Jennifer (opens sec.gov in a new tab) | |
| Zachary Jennifer | EVP, General Counsel | Option exercise | $1,137,909.43 | Form 4 for Zachary Jennifer (opens sec.gov in a new tab) | |
| Zachary Jennifer | EVP, General Counsel | Open-market sale | $10,718,494.55 | Form 4 for Zachary Jennifer (opens sec.gov in a new tab) | |
| DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | Open-market sale | $1,460,770.47 | Form 4 for DeLuca Richard R. (opens sec.gov in a new tab) | |
| DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | Open-market sale | $79,222.02 | Form 4 for DeLuca Richard R. (opens sec.gov in a new tab) |
A disclosure, not a signal to trade. Source: SEC EDGAR (Form 4). Older filings and the 90-day buying-and-selling read are part of Pro. See plans
How does MRK compare with its peers?
People who read MRK also read
Companies we do put a number on
Not investment advice. TickerWorth Score is a model output.
A descriptive, available-data snapshot and relative comparison — NOT a DCF, NOT a price target, and NOT investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public market data that can be wrong, stale or incomplete.